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ABSTRACT
This is the first study to examine the long-term effect 
of 5-aminolevulinic acid mainly on serum lipoproteins 
in dogs with hyperlipidemia. We studied 5 Miniature 
Schnauzer cases whose fasting serum total triglyceride 
and very-low-density lipoprotein of triglyceride levels 
were extremely high (635 ± 116 and 520 ± 92 mg/dL, 
respectively). Although the total cholesterol values were 
normal, the very-low-density lipoprotein of cholesterol 
level was high (49 ± 7 mg/dL). Each dog received a 
5-aminolevulinic acid supplement (5 mg/day) orally for 
6 months. The mean values of total triglyceride, very-
low-density lipoprotein of both triglyceride and choles-
terol decreased significantly after the treatment period 
(319 ± 29, 245 ± 18, and 27 ± 2 mg/dL, respectively, P 
< 0.05). Our present results may present evidence that 
5-ALA administration contributes to improvement of 
hyperlipidemia in Miniature Schnauzer.
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Hyperlipidemia in Miniature Schnauzers (MSs) is 
a breed-related lipid disorder,1, 2 which is character-
ized primarily by increased serum concentration of 
triglyceride (TG) and occasionally cholesterol (Chol), 
accompanied by the accumulation of either very-low-
density lipoprotein (VLDL) or a combination of VLDL 
and chylomicron (CM).2 Recent studies raised the 
possibility that hyperlipidemia in MS can cause several 
complications such as pancreatitis,3 hepatobiliary disor-
der,4 glomerular injury,5 ocular disease,6 and neurologi-
cal symptoms.7 Unfortunately, the cause of primary 
hyperlipidemia in this breed has not yet been fully 
elucidated, although the deficiency or decreased activity 
of lipoprotein lipase were formerly considered to be one 
factor of this disease.2 As for the treatment of canine 
hyperlipidemia, feeding the animals a low-fat diet is 
initially recommended.2 In addition, administration 
of lipid-lowering drugs such as omega-3 fatty acids,8 
fibrates,9 niacin,10 and statins11 is required in patients 
that do not sufficiently respond to dietary management. 
Notably, a recent study9 demonstrated the efficacy of 
bezafibrate, a fibrate, in treatment hyperlipidemia in 
dogs including MS. However, these agents are originally 
marketed as human drugs, and thereby veterinary drugs 
for the treatment of canine hyperlipidemia remains to be 
developed.
5-Aminolevulinic acid (5-ALA) is a natural 
δ-amino acid, and acts as a precursor to heme,12 which 
has an energy-generating function in the mitochon-
dria.13 Recent studies report that the administration 
of 5-ALA upregulates aerobic energy metabolism by 
increasing the activity and protein expression in the 
mitochondria of mice.12, 14 Hence, the administration 
of 5-ALA may result in an improvement in lipid and 
glucose metabolisms, and a reduction in obesity in 
obese mice.12, 15, 16 In Japan, 5-ALA supplement has 
been recently developed for dogs.17 The previous study 
confirmed that the effect of 3-month administration 
of 5-ALA on serum TG concentration in MS dogs17; 
however, the effects of longer-term administration on 
the lipoprotein concentration in the dogs have yet to be 
investigated. In this study, we assessed the 6-month ef-
fect of a commercially-available supplement of 5-ALA 
on serum lipoproteins in 5 closely related MS with 
hyperlipidemia.
SUBJECTS AND METHODS
The 5 dogs were brought to Anchor Trust Hospital 
(Tokyo, Japan) for medical checkup and were apparently 
healthy but overweight [bodyweight, 8.3–9.4 kg (Table 
1); body condition score, all 4/5]. They were privately 
owned and were closely related: case 1 was the mother 
of case 2, and case 2 was the mother of cases 3–5, which 
had been born at the same time. The mating partners of 
cases 1 and 2 were unrelated to all of the cases.
Complete blood cell counts and biochemical blood 
tests were carried out under fasting conditions (i.e., 
12 h or more after meals). Blood cell counts showed 
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Table 1. Details of 5 cases of Miniature Schnauzer dogs on the date of the first medical examination
Basic Information Case 1 Case 2 Case 3 Case 4 Case 5 Reference range*
Background









 Age (yr) 13 12 6 6 6
 Bodyweight 
 (Body condition score) 9.4 kg (4) 9.2 kg (4) 9.4 kg (4) 8.9 kg (4) 8.3 kg (4)
Biochemical test
 Total protein (g/dL) 7.9 8.0 7.1 8.0 8.5 5.4–7.1
 Albumin (g/dL) 3.0 3.5 3.7 3.6 2.3 2.6–3.3
 ALT (U/L) 43 163 96 40 56 21–102
 AST (U/L) 41 39 34 26 36 23–66
 ALP (U/L) 512 1008 235 183 130 20–156
 γ-GTP (U/L) 7.0 11.0 5.0 3.0 3.0 1.2–6.4
 Total Bilirubin (mg/dL) 0.4 0.2 0.2 0.2 0.2 0.1–0.5
 BUN (mg/dL) 21.8 21.3 20 11.8 16.1 10–28
 Creatinine (mg/dL) 1.0 1.2 1.1 0.7 1.1 0.4–1.8
 Glucose (mg/dL) 109 91 60 75 56 65–118
 Na (mEq/L) 150 148 149 147 149 141–152
 K (mEq/L) 5.3 5.5 4.4 4.3 4.4 4.4–5.4
 Cl (mEq/L) 107 103 109 110 112 105–115
 Lipase (U/L) 269 106 144 61 21 10–160
Endocrinology test
 T4 (μg/dL) 1.0 1.4 1.9 1.4 1.8 1.0–4.0
 FT4 (pmol/L) 5.7 7.7 18.5 11.5 15.2 7.7–47.6
 c-TSH (ng/mL) 1.99 0.84 0.61 1.23 0.4 0.05–0.42
 Basic cortisol (μg/dL) 4.8 2.8 1.5 1.9 1.1 2.0–6.0
TG-related lipoprotein
 Total TG (mg/dL) 1094 515 529 461 576 0–107
 CM-TG (mg/dL) 148 42 96 23 28 0–10
 VLDL-TG (mg/dL) 879 420 384 410 508 0–67
 LDL-TG (mg/dL) 39 18 31 19 24 3–38
 HDL-TG (mg/dL) 28 34 18 9 15 0–10
Chol-related lipoprotein
 Total Chol (mg/dL) 274 255 192 177 180 91–293
 CM-Chol (mg/dL) 10 3 7 2 2 0–10
 VLDL-Chol (mg/dL) 76 38 40 39 50 0–10
 LDL-Chol (mg/dL) 33 29 17 15 12 0–57
 HDL-Chol (mg/dL) 155 185 129 123 115 90–241
*Reference ranges of biochemical test were derived from the Textbook of Veterinary Internal Medicine,13 whereas those of endocrinol-
ogy test and lipoprotein analysis were indicated by IDEXX Laboratories, Inc. (Tokyo, Japan), and Spectrum Lab Japan Inc. (Tokyo, Ja-
pan), respectively. †Bold values mean the values outside each reference range. AST, aspartate transaminase; BUN, blood urea nitrogen; 
c-TSH, canine thyroid stimulating hormone; FT4, free thyroxine; γ-GTP, gamma-glutamyltranspeptidase; T4, thyroxine; yr, years.
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normal or insignificant abnormal values in all cases (data 
not shown). Blood biochemistry tests revealed that in 
some cases, higher values than reference range18 were 
observed in total protein, albumin, alanine aminotrans-
ferase (ALT), alkaline phosphatase (ALP), gamma-
glutamyltransferase, and lipase activity (Table 1).
The measurements of the serum concentration of 
hormones (T4, FT4, c-TSH, and basic cortisol) and TG- 
or Chol-related lipoproteins [CM, VLDL, low-density 
lipoprotein (LDL), and high-density lipoprotein (HDL)] 
were outsourced. High c-TSH concentrations were ob-
served in two cases, low FT4 concentration in one case, 
and a low concentration of basic cortisol in 3 cases. In 
all cases, fasting serum total triglyceride (T-TG), TG-
related lipoprotein of CM (CM-TG), VLDL (VLDL-TG), 
and HDL (HDL-TG) were much higher than normal. 
Fasting serum total cholesterol (T-Chol) fell within the 
reference range, whereas VLDL of Chol (VLDL-Chol) 
was relatively high. Based on the blood test results (i.e. 
high concentration of T-TG and several TG-related lipo-
proteins), we diagnosed all 5 cases as hyperlipidemia, 
and enrolled them in this open clinical trial.
This clinical trial was carried out for a total of 7 
months, consisting of 6-month treatment and 1-month 
wash-out periods. In the treatment period, 5-ALA 
was orally administered as a 5-mg supplement tablet 
(EneALA®, Neopharma Japan Co., Ltd, Tokyo, Japan) 
to each dog once per day, as recommended by the 
manufacturer. All of the cases have been given com-
mercial low-fat food (SELECT BALANCE SLIM, 
Vet’s Choice Japan Co., Ltd., Gifu, Japan) and no other 
treatment before and during the study period. Blood 
tests were conducted as described above at 3, 6, and 7 
months. The statistical analysis was carried out by using 
the commercially available computer soft (BellCurve 
for Excel®, Social Survey Research Information Co., 
Ltd., Tokyo, Japan). Temporal changes in test results 
were statistically analyzed by one-way repeated-mea-
sures analysis of variance with Bonferroni correction. 
Statistical significance was set as P < 0.05.
Informed consent and consent for the use of 
EneALA® were obtained from the owner, who also 
granted permission for the publishing of this case report. 
The clinical study in this study was conducted under an 
ethics committee-approved protocol in accordance with 
the Tottori University Animal Clinical Research Ethics 
Committee (approval number: H31-001).
RESULTS AND DISCUSSION
In this study, 5-ALA (5 mg/head) was administered 
once a day for 6 months, and no adverse effects were 
observed. Temporal changes in the mean serum 
concentrations of TG- and Chol-related lipoproteins in 
5 cases over 7 months are shown in Figs. 1(a) and 1(b), 
respectively. As for TG-lipoproteins, the values of T-TG, 
CM-TG, and VLDL-TG in all 5 cases remained to be 
higher than the reference range after 6-month treatment 
(range, 209-372 mg/dL), but the mean values of T-TG 
and VLDL-TG (mean ± SE) were significantly lower 
at 3 and 6 months than before treatment, respectively 
(P < 0.05). LDL-TG levels were slightly but signifi-
cantly lower at 3 months than initial values (P < 0.05). 
However, the concentrations of T-TG, VLDL-TG, and 
LDL-TG increased again one month after the treatment 
ended, indicating that the effects of 5-ALA are likely 
to be limited to the administration period only. These 
findings indicate that 5-ALA treatment cannot fully 
normalize but can decrease T-TG in MS with hypertri-
glyceridemia, mainly through a decrease of VLDL-TG. 
Unfortunately, the efficacy of 5-ALA supplement in this 
study was considered to be weaker than that of bezafi-
brate, which can normalize serum T-TG concentration 
in most dogs with primary hypertriglyceridemia.9 In 
order to promote the effective use of the 5-ALA supple-
ment, further study to verify the combined therapeutic 
effect with lipid-lowering drugs, including bezafibrate, 
and/or therapeutic diets is greatly anticipated.
In Chol-lipoproteins, a slight but significant 
decrease in the mean VLDL-Chol was observed during 
the 5-ALA treatment period compared with before 
treatment (P < 0.05). However, no significant differ-
ence in T-Chol before and during the 5-ALA treatment 
period was found. This implies that 5-ALA has little 
effect in reducing Chol-related lipoproteins. By contrast, 
Koganei et al.16 found that the administration of 5-ALA 
resulted in a decrease of T-Chol in diet-induced obese 
mice. Further studies are needed to clarify the effect of 
5-ALA on hypercholesteremia in dogs.
Lipid disorders may be due to primary or second-
ary factors in dogs,2 although in this study, it is likely 
that primary causes played a great role in hyperlipid-
emia as the dogs were extremely closely related, middle 
or old-aged MS, and all had elevated T-TG and VLDL-
TG.1, 2, 11 Such familial (genetic) hyperlipidemia is very 
common in humans,19 as well as dogs. Incidentally, sib-
pair linkage analysis has been conducted to identify the 
responsible genes of various familial diseases in human 
medicine,20 but demands an enormous amount of time. 
In contrast, the intergenerational studies in companion 
animals, such as this study, can be finished in a shorter 
time because of their short life-span, and thus would 
contribute to advance understanding of the similar 
diseases in humans.
As for secondary causes of hyperlipidemia, all 
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cases were overweight, which can affect serum lipo-
protein concentrations.21, 22 Blood tests revealed that all 
cases had normal fasting serum glucose levels, essen-
tially ruling out diabetes mellitus. Case 1 had low FT4 
levels, and cases 1 and 4 showed normal T4 but high 
TSH concentrations, indicating potential hypothyroid-
ism or occasional thyroid axis alteration.23 Pancreatitis 
might also be associated with hypertriglyceridemia in 
case 1,3 because of the elevated lipase activity.
The bodyweight of all cases decreased with 5-ALA 
treatment, and the mean (± SE) bodyweight (kg) was 
significantly lower after 3 (8.38 ± 0.17), 6 (7.82 ± 0.16), 
and 7 (7.38 ± 0.17) months, compared with that prior 
to treatment (9.04 ± 0.21, P < 0.01). Thus, 5-ALA 
treatment may contribute to weight loss in overweight 
dogs, which is supported by the findings of the obesity 
model in mice.12, 15, 16 The biochemical blood tests after 
6 months of 5-ALA treatment indicated a decrease in 
ALP in cases 1, 2, 3, and 4 to 361, 539, 161, and 101 U/
L, respectively. ALT in case 2 decreased to 79 U/L, and 
lipase activity in case 1 decreased to 163 U/L. Thus, 
5-ALA administration might contribute to subclinical 
hepatobiliary disorder and/or pancreatitis possibly 
because of the improvement of hypertriglyceridemia in 
these cases. On the other hand, the mean T4 levels (μg/
dL) were kept nearly constant during the clinical trial 
period (1.52 ± 0.19, 1.64 ± 0.16, and 1.44 ± 0.12 at 3, 6, 
and 7 months, respectively), and thus 5-ALA treatment 
is unlikely to affect T4 concentration in dogs. In addi-
tion, the mean concentrations of heme-related products, 
i.e., hemoglobin (g/dL) and total bilirubin (mg/dL) at 3 
(15.5 ± 0.73 and 0.26 ± 0.02), 6 (16.5 ± 0.86 and 0.26 ± 
0.04), and 7 (16.9 ± 0.33 and 0.24 ± 0.05), respectively, 
did not differ from those before treatment, although the 
previous study reported that in mildly hyperglycemic 
human subjects, blood concentrations of these products 
increased by 5-ALA treatment.24 Thus, the effect of 
5-ALA administration on heme-related products might 
be different between dogs and humans.
This study has several limitations. Firstly, we 
focused on a small number of MS dogs that had very 
close blood relationships. Secondly, it remains unknown 
whether 5-ALA has any efficacy in dogs with severe 
hyperlipidemia-related complications. Thirdly, the start 
timing of effectiveness of 5-ALA and the enhancement 
of the efficacy by an increased dose were not fully clari-
fied in this study, and thus should be verified by further 
studies with modified test protocol.
In conclusion, to our knowledge, this is the first 
study to report on the improvement effects of long-
term administration of 5-ALA on VLDL-TG and LDL-
TG, in addition to T-TG, in MS dogs. There may be 
several possible explanations for the effects of 5-ALA. 
As shown in this study, 5-ALA treatment can help the 
elimination of obesity, which can increase the risk of 
high concentrations of T-TG and VLDL-TG,25 possibly 
because of increase in activity of mitochondrial cyto-
chrome c oxidase and production of ATP.14 Additionally, 
5-ALA may induce a reduction in white adipose tissue 
volume and expression of uncoupling protein-1 in brown 
adipose tissue.26 Furthermore, 5-ALA can increase 
expression of lipoprotein lipase and suppress expression 
of fatty acid synthase, and thereby may improve liver 
lipid metabolism.16 Our results raise expectations that 
the 5-ALA supplement can be available as a treatment 
option of canine hyperlipidemia. Further, large-scale 
clinical studies are needed to fully demonstrate the ef-
ficacy of 5-ALA for hyperlipidemia in dogs.
Fig. 1. The temporal changes of the blood concentrations (mean ± SE) of TG-related lipoproteins (a) and Chol-related lipoproteins (b) in 
5 cases of Miniature Schnauzer dogs during the observation period. P < 0.05 vs. 0 month in T-TG (*), VLDL (†), LDL (‡), and CM (§). 
The results on T-TG concentrations at 0 and 3 months were previously reported.17
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